Lipoprotein-associated phospholipase A 2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 181-187

  Massot, Andreu ^a   Pelegri, Dolors ^a   Penalba, Anna ^a   Arenillas, Juan ^b   Boada, Cristina ^a   Giralt, Dolors ^a   Ribó, Marc ^a   Molina, Carlos A ^a   Rosell, Anna ^a   Alvarez Sabín, José ^a   Chacón, Pilar ^a   Rovira, Alex ^a   Delgado, Pilar ^a   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

Author keywords

Cardiovascular recurrence risk; Intracranial atherosclerosis; Intracranial stenoses; Lipoprotein associated phospholipase A 2; Lp PLA 2; Stroke recurrence risk

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DOPPLER ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; BRAIN DISEASES; CEREBROVASCULAR CIRCULATION; CORONARY ARTERY DISEASE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK; RISK FACTORS; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 80052272950     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.031     Document Type: Article

References (30)

1. Sacco R., Kargman D.E., Quiong Gu, Zamanillo M.C. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995, 26:14-20.
2. Wong K.S., Huang Y.N., Gao S., et al. Intracranial stenosis in Chinese patients with acute stroke. Neurology 1998, 50:812-813.
3. Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al. Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005, 352:1305-1316.
4. Arenillas J.F., Molina C.A., Montaner J., et al. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke 2001, 32:2898-2904.
5. Arenillas J.F., Alvarez-Sabín J., Molina C., et al. C-reactive protein predicts further ischemic events in first-ever TIA and stroke patients with intracraneal large-artery occlusive disease. Stroke 2003, 34:2463-2470.
6. Arenillas J.F., Álvarez-Sabin J., Molina C.A., et al. Progresión of symptomatic intracraneal large-artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis. Stroke 2008, 39:1456-1463.
7. 2 stability before and after stroke and myocardial infarction. Stroke 2009, 40:3233-3237.
8. Cederholm A., Svenungsson E., Stengel D., et al. Platelet-activating factor-acetylhydrolase and other novel risk and protective factors for cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2004, 50:2869-2876.
9. 2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009, 23:93-101.
10. 2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden. Atherosclerosis 2008, 200:191-198.
11. Robins S.J., Collins D., Nelson J.J., Bloomfield H.E., Asztalos B.F. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2008, 28:1172-1178.
12. 2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the atherosclerosis risk in communities (ARIC) study. Stroke 2009, 40:376-381.
13. Arenillas J.F., Molina C.A., Chacón P., et al. High lipoproteína (a), diabetes and the extent of symptomatic intracranial atherosclerosis. Neurology 2004, 63:27-32.
14. Arenillas J.F., Massot A., Alvarez-Sabín J., et al. C-reactive protein gene C1444T polymorphism and risk of recurrent ischemic events in patients with symptomatic intracranial atherostenoses. Cerebrovasc Dis 2009, 28:95-102.
15. 2, and outcome after ischemic stroke. Arch Intern Med 2006, 166:2073-2080.
16. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004, 109:837-842.
17. 2 activity and risk of recurrent stroke. Cerebrovasc Dis 2009, 27:42-50.
18. 2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008, 51:1115-1122.
19. 2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005, 111:570-575.
20. 2 activity predicts early stroke recurrence [abstract]. Stroke 2007, 38:458.
21. Thompson A., Gao P., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544. Lp-PLA(2) Studies Collaboration.
22. 2 as a marker for atherosclerosis. Curr Atheroscler Rep 2007, 9:97-103.
23. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007, 27:1411-1416.
24. 2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 2009, 40:2332-2336.
25. 2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
26. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A(2), plateletactivating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000, 150:413-419.
27. Cushman M., Legault C., Barrett-Connor E., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999, 100:717-722.
28. 2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2006, 26:631-636.
29. 2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008, 39:1448-1455.
30. Cao J.J., Thach C., Manolio T.A., et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly. The cardiovascular health study. Circulation 2003, 108:166-170.